logo_web
  • Clinical Trials
    • Management of medication
    • Management of reimbursement of expenses to patients
    • Supply of medical devices
    • Destruction
    • Calibration of medical devices
    • Import and labeling of medication
    • Masking. Placebos manufacturing
  • Blog
  • Quality
    • Certifications
    • RSE
  • Clients
  • Patient Reimbursement Forms
    • Validation / Expense Reimbursement Sheet
✕
  • Clinical Trials
    • Management of medication
    • Management of reimbursement of expenses to patients
    • Supply of medical devices
    • Destruction
    • Calibration of medical devices
    • Import and labeling of medication
    • Masking. Placebos manufacturing
  • Blog
  • Quality
    • Certifications
    • RSE
  • Clients
  • Patient Reimbursement Forms
    • Validation / Expense Reimbursement Sheet

Health commitment to the pharmaceutical industry’s Strategic Plan to avoid losing 8,000 million euros

“We are going to create a favourable environment”. This statement by José Manuel Miñones is the first step towards a roadmap that would highlight the key contributions of the sector

El ministro de Sanidad, José Miñones, en el encuentro que organiza Farmaindustria en la Universidad Internacional Menéndez Pelayo

Source: elmundo.es

Innovation in the European pharmaceutical industry is ‘at stake’ in the new European legislation. In the midst of the regulatory reform process, which is necessary because it has not been updated for 20 years, there are details such as the reduction of incentives and its impact on competitiveness with markets such as the United States or Asia that cloud a possible advance in the regulation of the approval of new 21st century therapies that require updated codes.

Spain plays a leading role with the Spanish Presidency of the Council of the European Union. José Manuel Miñones, Minister of Health of the Spanish Government, has announced that one of the key issues on the table at the meeting of EU presidents in October will be the Open Strategic Autonomy (OSA) project and its impact on industry. “This was discussed at the informal meeting of health ministers last July in the Canary Islands”.

This initiative seeks to ensure the EU’s strategic autonomy in key sectors such as energy and health, through recommendations on issues such as the availability and production of active pharmaceutical ingredients (APIS). The Spanish Presidency is finalising the draft to be presented in October, which will seek an agreement to ensure that the supply chains of medicines are diversified and secure so that Europe can meet its needs, explained the acting Minister of Health.

This announcement was made at the annual meeting of the Spanish pharmaceutical industry, which is currently being held in Santander by Farmaindustria, the employers’ association for laboratories. In his speech, Miñones also made it clear that the Strategic Plan for the Pharmaceutical Industry, which he presented to the government last December, will be implemented. “We are going to create a favourable environment,” the minister remarked.

Spain has a lot at stake: an investment of 8,000 million, 4,500 young jobs and 48,000 million in exports over the next three years. So it cannot afford to miss this opportunity. And that is why he has not hesitated to describe industry as “a fundamental ally if we want to continue moving forward”.

Farmaindustria, through the intervention of its director general, has taken up the gauntlet. Juan Yermo stated the need for “appropriate government policies, good governance, effective public-private collaboration and sustainable investment in healthcare”.

Yermo recalled the axes on which this roadmap pivots. “The three main priorities have not changed. Improving access to medicines for patients, boosting R&D to consolidate the biomedical innovation ecosystem, and strengthening industrial capacities and creating resilient medicine supply chains”.

For this reason, Miñones said they will develop “legislative measures to get the medicine to the patient. We will combine this with keeping older medicines on the market, which will be those on the published list of strategic medicines.

Natalie Moll, director general of the European Federation of Pharmaceutical Industries Associations (EFPIA), also pointed out in her speech at the conference that “the loss of incentives to provide the necessary access to medicines is an obstacle to return on investment”.

And as key examples of why this is essential, Yermo put concrete figures on the table. “More than 70% of the increase in life expectancy between 2000 and 2009 in Western countries is due to the use of innovative medicines. And in Spain, “according to the latest study by Professor Lichtenberg of Columbia University, cancer drugs reduce cancer deaths by almost 30% each year. And, for example, in cardiovascular diseases, the reduction in mortality thanks to medicines is 50%.

In the afternoon session, César Hernández, director general of the Common Portfolio of Services of the National Health System and Pharmacy of the Ministry of Health, focused on the necessary balance between incentives, access and pharmaceutical sustainability. “The problem is how to put in a box: the benefits, for a number of patients and each with a price”.

“All this is complex and has not been solved anywhere in the world,” he stressed, while insisting that “we have to look for the best solution that suits our needs”. Hernández also acknowledged that while it takes a long time to access new therapies, Spain is a leader in clinical trials and “a large number of patients benefit from them”.

Related entries

19 September, 2023

The pharmaceutical industry’s plan to expand clinical trials in primary care


Leer más
12 September, 2023

Improving patient access to innovative medicines and boosting R&D and manufacturing in Spain are the main priorities of the pharmaceutical industry


Leer más
25 July, 2023

The rise of combination therapies in cancer opens up an opportunity for patients, but requires improved access procedures


Leer más

Recent Posts

  • The pharmaceutical industry’s plan to expand clinical trials in primary care
  • Health commitment to the pharmaceutical industry’s Strategic Plan to avoid losing 8,000 million euros
  • Improving patient access to innovative medicines and boosting R&D and manufacturing in Spain are the main priorities of the pharmaceutical industry
  • The rise of combination therapies in cancer opens up an opportunity for patients, but requires improved access procedures
  • The 22nd Meeting of the Spanish Pharmaceutical Industry will focus on the reform of European legislation and its impact on Spain

Contacta con nosotros


Tfno: +34 955.77.67.67
Fax: +34 955.77.65.56
info@distefar.net


Distefar del Sur
Sede Central

Distefar del Sur S.L.
Av. Umbrete, 58,
41110 Bollullos de la Mitación, Sevilla

Sede Madrid

Calle de Zurbano, 45, 28010 Madrid

CENTRAL

Pol. PIBO. Avda. de Gines, 14
+34 955 776 767 /+34 692 454 913
41110 Bollullos de la Mitación (Sevilla)

DELEGACIÓN MADRID

+34 674 575 115
28010 Madrid

Enlaces de interés

  • Aviso Legal
  • Política de privacidad
  • Política de cookies
  • Contacto

© 2023 Distefar del Sur SL. Todos los derechos reservados. agencianodo.com

  • No translations available for this page
  • Contact
  • Private Zone
  • English

    [recaptcha]

    In accordance with the provisions of Regulation (EU) 2016/679 and Organic Law 3/2018 regarding Data Protection, we inform you that the data you provide in this form will be incorporated into a file owned by DISTEFAR DEL SUR, SL domiciled in the C / Umbrete 58, (Pol. Ind. Pibo), 41110 of Bollullos de la Mitación (Seville), in order to manage your request.

    In this regard, and if you wish to exercise your rights of access, rectification, cancellation, opposition, portability and limitation, please send a written communication to DISTEFAR DEL SUR, SL, to the address indicated above or to info@distefar.com, attaching copy of your National Identity Document or equivalent identification document.

    Basic information about Data Protection

     Epigraph

    Basic information Data Protection

    Responsable

    DISTEFAR DEL SUR, S.L.

    Purpose

    Process your inquiry / request
    Detailed information on Data Protection

    Legitimation

    Consent
    Detailed information on Data Protection

    Recipients

    It is not expected to carry out data communications to third parties, except legal obligation
    Transfers of data to third countries outside the European Union will not be carried out
    Detailed information on Data Protection

    Rights

    You have the right of access, rectification, deletion, portability of your data, as well as limitation or opposition to your treatment, as detailed in Detailed information on Data Protection

    Additional Information

    You can consult the additional and detailed information on data protection by clicking here Detailed information on Data Protection

    All the data requested / The fields marked with * in the form are mandatory, if not filled in DISTEFAR DEL SUR, S.L. will not be able to meet your request.